BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations.

Sevindik, Ömür GökmenChen, ChangYang, JingFarooqui, Mohammed Z. H.Paszkiewicz-Kozik, Ewa2024-03-132024-03-132023Sevindik, Ö. G., Chen, C., Yang, J., Farooqui, M. Z. H. ve Paszkiewicz-Kozik, E. (2023). BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL, 02-06 June, 2023.0732-183X1527-7755https://hdl.handle.net/20.500.12511/12364[Abstract Not Available]eninfo:eu-repo/semantics/closedAccessSmall Lymphocytic Lymphoma (SLL)Chronic Lymphocytic Leukemia (CLL)Untreated PatientsBELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations.Conference Object4116Q1001053772005459